 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
upgrad overweight
sinc key dmd genetherapi data
believ market miss near-term catalyst
could drive higher includ clear path approv
fda valuat attract believ
time step back
recent pullback provid opportun near pre-dmd genetherapi
level without take binari risk declin vs
nasdaq biotech index sinc move initi dmd
data announc believ declin occur sharehold
transit mostli short-term long-term orient investor
importantli believ major bear case emerg prospect
dmd genetherapi program therapi see major catalyst
includ fda feedback manag plan acceler path
market clear upsid driver competit manufactur could
present headwind believ management solv manufactur hurdl quickli
believ management lead competit significantli reduc competit
threat highlight key valuat catalyst
manufactur updat manag recent announc clinic
program place hold due plasmid contain dna fragment
manag address issu move gmp- plasmid
expect issu solv short order manag alreadi
secur suppli new plasmid see risk start
pivot cohort believ manag bridg commerci
suppli crossov period pivot studi
fda meet cohort manag plan add placebo
control cohort current phi/ii genetherapi studi cohort
expect includ patient random month follow-
manag remain track meet fda final
plan pivot cohort base case remain data
approv note fda could offer aggress timelin
market would upsid versu expect see clariti
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
timelin market key upsid driver
competit updat two key genetherapi competitor pfizer
solid expect report initi data well
sarepta pivot plan place therapi pf-
first patient dose march indic
dose first patient earn call expect
initi data expect level dystrophin product
competit therapi sarepta product thu see
risk competitor issu time sarepta remain well
larg market opportun reflect current valuat believ dmd
incid patients/year us recur market
opportun assum annual price minimum believ
revenu stream could valu minimum
market cap howev given dmd patient us
also larg treatment bolu conserv model global
peak sale see upsid term time peak peak sale
highlight bull case success across dmd lgmd genetherapi could
drive high consider could drive
potenti treat older patient initi studi treat patient
year given express data cardiac muscl like
genetherapi could also benefit non-ambulatori patient preserv
cardiac function would expect manag detail studi
patient see non-ambulatori patient possibl market
potenti treat young patient disord treat
earli diseas process could product
would expect patient treat safeti databas
larg enough manag could engag regul issu
get clariti issu could help consensu fulli valu
price current model treatment howev
dmd treatment cost high higher price could
larg impact valuat watch novarti price
expand exon antibodi titer current treatment
microdystrophin approach limit patient mutat exon
repres dmd patient patient need
neg antibodi patient like
antibodi thu current patient could treat
approach manag either redos strategi
expand antibodi titer limit could remov antibodi issu
test manag may abl expand number
amen exon howev timelin either expans clear
clariti data could drive uptak patient repres
anoth larg pool revenu upsid
limb girdl muscular dystrophi lgmd upsid option driver
add bull case manag recent acquir broad lgmd
genetherapi program diseas anoth muscl disord similar us
preval dmd vs dmd manag current
target five type recess lgmd disord myo-
lead product candid expect initi
data could lead investor begin valu program given
share platform dmd genetherapi believ good
potenti success
background dmd lgmd genetherapi
duchenn muscular dystrophi dmd genet diseas boy suffer
sever muscl destruct death due mutat gene protein
dystrophin import mainten muscl fiber cell membran
sarepta develop current market exondi treatment
duchenn muscular dystrophi patient amen exon skip
util dmd expertis compani develop potenti cur
gene therapi diseas
compani recent present transform genetherapi data data
initi patient treat microdystrophin dmd genetherapi suggest
potenti normal diseas process boy dmd timelin market
could earli late earli day fiber
dystrophin posit western blot sarepta approach indic
dystrophin product nationwid children hospit approach adjust
certain tissu paramet yield significantli
expect consensu dystrophin express current exon
skip drug express micro-dystrophin robust mean gene express
mean intens fiber compar normal control
reduct serum ck first patient patient
near normal last seriou advers event management note
two patient elev gamma-glutamyl transferas
resolv within week treatment steroid management comment data
exceed even expect
current two competitor space solid bioscienc cover
pfizer/bamboo cover david rising solid bioscienc current
micro-dystrophin gene transfer compound clinic phase ignit dmd trial
previous place clinic hold follow seriou advers event character
decreas platelet count follow reduct red blood cell count transient
renal impair evid complement activ hold lift
manag expect report initi data pre-specifi interim analysi
develop microdystrophin genetherapi
treatment dmd first patient dose march expect initi data
boy
base case scenario assum continu strength exondi well
approv exon skip drug assum approv dmd gene
therapi sale start next catalyst fda guidanc path
market expect convers fda favor
limb-girdl muscular dystrophi lgmd group approxim differ
disord collect preval sarepta lgmd gene
therapi portfolio target patient collect like mani muscular
dystrophi diseas lgmd caus defect dystrophin-associ protein
complex part complex sarcoglycan defici sarcoglycan lead
dystrophin defici sarepta multipl drug target multipl part protein
complex beta-sarcoglycan alpha-sarcoglycan
gamma sarcoglycan dysferlin latter two
support muscl membran repair subtyp lgmd differ slightli preval
shown
request pre-ind
expect see data treatment target
beta-sarcoglycan target anoctamin mirror sever
form dmd signific cardiomyopathi death earli adulthood
system phi/iia iv trial start biopsi data gather earli
long-term prospect sarepta dmd franchis drive valu
long-term prospect sarepta dmd franchis
pt deriv dcf use discount rate
termin growth beyond valu sarepta dmd franchis
bull scenario assum exondi achiev rapid launch sale
taper peak penetr achiev also assum aggress sale
exon approv well signific updat genetherapi
lgmd add upsid
base case scenario assum continu strength exondi well
approv golodirsen camisersen modest risk adjust
intern sale assum success genetherapi
assum lower peak penetr exondi approv golodirsen
modest sale approv camisersen downstream eros usag
includ revenu altern mutat
overweight thesi base
strong initi dmd genetherapi data
manag abil captur signific
market share dmd genetherapi
product genetherapi remain riski
believ initi data derisk program
provid signific upsid potenti
base busi exon skip drug
pipelin larg divers offer lgmd
potenti upsid driver
time market clinic success
risk achiev price
updat dmd genetherapi program
includ risk relat manufactur
current clinic hold
failur secur addit regulatori
approv obtain reimburs could
data competitor compani could
either posit neg impact
sarepta posit dmd market
summit therapeut present phii open label data dmd
safeti signal dose
ind next ppmo candid
phase studi preliminari result
biopsi data gather
ind file follow-on ppmo compound
